Methylenedioxymethamphetamine (MDMA, Ecstasy) Induced Changes in Drug Metabolism: Gender and Genetic Polymorphisms

A Phase I, non-randomised, single-group study in healthy volunteers to evaluate the roles of CYP2D6, CYP3A4 and CYP1A2 (using dextromethorphan and caffeine probes) and COMT in MDMA metabolism, and to assess gender differences and selected genetic polymorphisms (CYP2D6, COMT, SERT) on MDMA pharmacokinetics and effects.

Participants received a single oral dose of MDMA (1.5 mg/kg reported; registry notes range 75–100 mg). Outcomes include pharmacokinetic measures, metabolic probe responses, and genotype–phenotype associations.